NEW DELHI, Oct 10: The Centre’s decision to cap trade margins on non-scheduled anti-cancer medicines at 30 per cent is expected to provide financial relief to cancer patients and their families, who often face substantial expenses during prolonged treatment.
The Department of Pharmaceuticals announced the measure on October 8, saying the initiative could reduce the maximum retail prices (MRPs) of affected medicines by up to 70 per cent and generate estimated annual savings of around ₹2,500 crore for patients. The decision extends price protection to anti-cancer medicines that are not covered under the existing list of drugs subject to government-fixed ceiling prices.
The move comes amid growing concerns about the affordability of cancer care in India, where treatment costs can include medicines, diagnostic tests, hospitalisation, surgery, radiation therapy and repeated medical consultations. For many households, the financial burden extends beyond the initial diagnosis, as patients may require treatment over several months or longer.
Under the new mechanism, trade margins on the covered medicines will be restricted to 30 per cent of their maximum retail price. An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be included, after which the National Pharmaceutical Pricing Authority (NPPA) will issue the necessary notification.
The measure is intended to address excessive mark-ups in the pharmaceutical supply chain and improve access to medicines without compromising their availability.
Broader price protection for cancer medicines
Cancer medicines are sold through a market that includes branded and generic products, imported and domestically manufactured formulations, and patented and non-patented treatments. While medicines on the scheduled list are already subject to government price controls, non-scheduled drugs have not been covered by the same ceiling-price framework.
The latest decision seeks to narrow this gap by regulating trade margins on non-scheduled anti-cancer drugs. Reports on the policy have indicated that the proposed coverage could extend to around 110 medicines, including 35 patented drugs, although the final list will be determined through the official process.
The government expects the intervention to make a significant difference to patients who purchase expensive medicines through pharmacies and other authorised distribution channels. The actual reduction, however, will depend on the price structure of individual products and the margins currently applied at different stages of distribution.
The distinction between a trade-margin cap and a reduction in the manufacturer’s price is important. A margin cap limits the amount that can be added through the distribution and sale chain; it does not automatically mean that the underlying production or acquisition cost of every medicine will fall by the same percentage.
Consequently, the impact could vary across different treatments. Medicines carrying particularly high distribution mark-ups may experience substantial price reductions, while products whose prices are primarily driven by manufacturing costs, patents or other factors may see a more limited change.
Previous intervention offers a precedent
India has previously used trade-margin regulation to address the high cost of cancer medicines. In 2019, the NPPA capped margins on 42 selected non-scheduled anti-cancer drugs following government directions.
According to official information, the earlier intervention led to reductions of up to 91 per cent in the maximum retail prices of some medicines. The experience provided a precedent for extending the policy to a wider range of treatments.
The latest decision builds on that approach by targeting a broader segment of the non-scheduled anti-cancer drug market. Its intended benefits include reducing excessive mark-ups, improving price transparency and helping patients manage recurring treatment expenses.
For families dealing with cancer, even a partial reduction in medicine costs can be important. Patients may need several drugs as part of a treatment plan, and some therapies require repeated purchases. Lower prices could help reduce the amount families pay directly, although the final benefit will depend on the medicines prescribed and their inclusion in the notified list.
Affordability remains a wider challenge
Despite the proposed controls, experts and industry observers have pointed out that drug pricing is only one part of the larger affordability challenge.
Cancer treatment can involve several cost components beyond medicines, including specialist consultations, diagnostic procedures, surgery, radiotherapy, inpatient care and follow-up monitoring. A reduction in the price of a drug may therefore improve affordability without necessarily making the entire treatment course inexpensive.
The issue is particularly relevant for advanced therapies, including certain targeted treatments and immunotherapies, whose underlying prices can remain high even when distribution margins are restricted. The extent to which a margin cap improves access to such medicines will depend on how much of their final retail price comes from the distribution chain rather than the manufacturer’s initial price.
The government will also need to ensure that the new restrictions do not create unintended supply problems. Maintaining the availability of medicines is critical because interruptions in treatment can have serious consequences for patients.
The Department of Pharmaceuticals has said the policy is intended to protect patients while ensuring the continued availability of life-saving medicines. The effectiveness of the measure will depend on implementation, monitoring and compliance by manufacturers, distributors, stockists and retailers.
Monitoring and implementation will be crucial
The final notification by the NPPA will be an important step in determining how the policy operates in practice. The list of covered medicines, the application of the margin cap and the monitoring of retail prices will shape the extent of relief available to patients.
Clear communication will also be necessary so that patients, hospitals and pharmacies can identify the medicines covered by the rules and understand the applicable prices.
Effective oversight can help prevent excessive mark-ups from reappearing through other parts of the supply chain. It can also provide a mechanism for identifying discrepancies between notified prices and the amounts charged to consumers.
Patients and caregivers should continue to obtain medicines through authorised channels and consult their treating doctors before making any changes to prescribed treatment. A price reduction should not be interpreted as a reason to switch medicines without medical advice.
The government’s estimated annual savings of ₹2,500 crore represent the anticipated benefit of the policy rather than a guarantee that every cancer patient will experience an identical reduction in expenses.
A step towards more affordable treatment
The 30 per cent trade-margin cap marks a further effort to use price regulation to improve access to cancer medicines. By extending controls to non-scheduled drugs, the government is seeking to address a segment of the market where distribution mark-ups have attracted scrutiny.
The coming weeks will be important as the expert committee finalises the medicines covered and the NPPA issues the relevant notification. The practical outcome will be judged by whether patients see lower prices at pharmacies, whether the savings are sustained and whether essential treatments remain readily available.
While the measure does not resolve every financial challenge associated with cancer care, it could provide meaningful relief to households facing high medicine bills. Its longer-term success will depend on transparent implementation, effective enforcement and continued efforts to make diagnosis and treatment accessible to patients across the country.